An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

Molecular Cell

Volumn 12, Issue 3, 2003, Pages 541-552

  Burgess, Antony W ^a,b   Cho, Hyun Soo ^e,f   Eigenbrot, Charles ^g   Ferguson, Kathryn M ^h   Garrett, Thomas P J ^a,c   Leahy, Daniel J ^f   Lemmon, Mark A ^h   Sliwkowski, Mark X ^g   Ward, Colin W ^a,d   Yokoyama, Shigeyuki ^i,j,k  

^a Department of Civil and Environmental Engineering   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d CSIRO   (Australia)

^e Yonsei University   (South Korea)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g GENENTECH INC   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ RIKEN YOKOHAMA INSTITUTE   (Japan)

^j UNIVERSITY OF TOKYO   (Japan)

^k RIKEN HARIMA INSTITUTE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; BETACELLULIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIGEN; EPIREGULIN; ERBB RECEPTOR; ERBB RECEPTOR ANTIBODY; GROWTH FACTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; LIGAND; PERTUZUMAB; PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

AUTOPHOSPHORYLATION; CANCER RESEARCH; DIMERIZATION; DRUG RECEPTOR BINDING; LIGAND BINDING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RNA PROCESSING; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

HOMO;

EID: 10744230127     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(03)00350-2     Document Type: Review

References (88)

1. Abe Y., Odaka M., Inagaki F., Lax I., Schlessinger J., Kohda D. Disulphide bond structure of human epidermal growth factor receptor. J. Biol. Chem. 273:1998;11150-11157.
2. Adams T.E., Epa V.C., Garrett T.P.J., Ward C.W. Structure and function of the type 1 insulin-like growth factor receptor. Cell. Mol. Life Sci. 57:2000;1050-1093.
3. Agus D.B., Akita R.W., Fox W.D., Lewis G.D., Higgins B., Pisacane P.I., Lofgren J.A., Tindell C., Evans D.P., Maiese K.et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2:2002;127-137.
4. Arteaga C.L. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin. Oncol. 29:2002;3-9.
5. Arteaga C.L. ErbB-targeted therapeutic approaches in human cancer. Exp. Cell Res. 284:2003;122-130.
6. Bajaj M., Waterfield M.D., Schlessinger J., Taylor W.R., Blundell T. On the tertiary structure of the extracellular domains of the epidermal growth factor and insulin receptors. Biochim. Biophys. Acta. 916:1987;220-226.
7. Berezov A., Chen J., Liu Q., Zhang H.T., Greene M.I., Murali R. Disabling receptor ensembles with rationally designed interface peptidomimetics. J. Biol. Chem. 277:2002;28330-28339.
8. Carter P., Fendly B.M., Lewis G.D., Sliwkowski M.X. Development of Herceptin. Breast Disease. 11:2000;103-111.
9. Chantry A. The kinase domain and membrane localization determine intracellular interactions between epidermal growth factor receptors. J. Biol. Chem. 270:1995;3068-3073.
10. Cho H.-S., Leahy D.J. Structure of the extracellular region of HER3 reveals an interdomain tether. Science. 297:2002;1330-1333.
11. Cho H.-S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W. Jr., Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 421:2003;756-760.
12. Citri A., Skaria K.B., Yarden Y. The deaf and the dumb. the biology of ErbB-2 and ErbB-3 Exp. Cell Res. 284:2003;54-65.
13. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6:2000;443-446.
14. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the newborn animal. J. Biol. Chem. 237:1960;1555-1562.
15. de Larco J.E., Todaro G.J. Epithelioid and fibroblastic rat kidney cell clones. epidermal growth factor (EGF) receptors and the effect of mouse sarcoma virus transformation J. Cell. Physiol. 94:1978;335-342.
16. de Vos A.M., Ultsch M., Kossiakoff A.A. Human growth hormone and extracellular domain of its receptor. Crystal structure of the complex Science. 255:1992;306-312.
17. Di Fiore P.P., Pierce J.H., Kraus M.H., Segatto O., King C.R., Aaronson S.A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 237:1987;178-182.
18. Domagala T., Konstantopoulos N., Smyth F., Jorissen R.N., Fabri L., Geleick D., Lax I., Schlessinger J., Sawyer W., Howlett G.J.et al. Stoichiometry, kinetic and binding analysis of the interaction between epidermal growth factor (EGF) and the extracellular domain of the EGF receptor. Growth Factors. 18:2000;11-29.
19. Downward J., Yarden Y., Mayes E., Scrace G., Totty N., Stockwell P., Ullrich A., Schlessinger J., Waterfield M.D. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 307:1984;521-527.
20. Elleman T.C., Domagala T., McKern N.M., Nerrie M., Lonnqvist B., Adams T.E., Lewis J., Lovrecz G.O., Hoyne P.A., Richards K.M.et al. Identification of a determinant of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain. Biochemistry. 40:2001;8930-8939.
21. Falls D.L. Neuregulins. functions, forms, and signaling strategies Exp. Cell Res. 284:2003;14-30.
22. Ferguson K.M., Darling P.J., Mohan M.J., Macatee T.L., Lemmon M.A. Extracellular domains drive homo- but not hetero-dimerization of erbB receptors. EMBO J. 19:2000;4632-4643.
23. Ferguson K.M., Berger M.B., Mendrola J.M., Cho H.-S., Leahy D.J., Lemmon M.A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell. 11:2003;507-517.
24. Garrett T.P.J., McKern N.M., Lou M., Frenkel M.J., Bentley J.D., Lovrecz G.O., Elleman T.C., Cosgrove L.J., Ward C.W. Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor. Nature. 394:1998;395-399.
25. Garrett T.P.J., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Zhu H.J., Walker F., Frenkel M.J., Hoyne P.A.et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor-α Cell. 110:2002;763-773.
26. Garrett T.P.J., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Kofler M., Jorissen R.N., Nice E.C., Burgess A.W., Ward C.W. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell. 11:2003;495-505.
27. Gotoh N., Tojo A., Hino M., Yazaki Y., Shibuya M. A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor. Biochem. Biophys. Res. Commun. 186:1992;768-774.
28. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16:1997;1647-1655.
29. Groenen L.C., Nice E.C., Burgess A.W. Structure-function relationships for the EGF/TGF-alpha family of mitogens. Growth Factors. 11:1994;235-257.
30. Gullick W.J. A new model for the interaction of EGF-like ligands with their receptors. the new one-two Eur. J. Cancer. 30A:1994;2186.
31. Guy P.M., Platko J.V., Cantley L.C., Cerione R.A., Carraway K.L. III. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA. 91:1994;8132-8136.
32. Harris R.C., Chung E., Coffey R.J. EGF receptor ligands. Exp. Cell Res. 284:2003;2-13.
33. Himanen J.P., Rajashankar K.R., Lackmann M., Cowan C.A., Henkemeyer M., Nikolov D.B. Crystal structure of an Eph receptor-ephrin complex. Nature. 414:2001;933-938.
34. Holbro T., Civenni G., Hynes N.E. The ErbB receptors and their role in cancer progression. Exp. Cell Res. 284:2003;99-110.
35. Horan T., Wen J., Arakawa T., Liu N., Brankow D., Hu S., Ratzkin B., Philo J.S. Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3. J. Biol. Chem. 270:1995;24604-24608.
36. Hubbard S.R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16:1997;5572-5581.
37. Hubbard S.R., Till J.H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 69:2000;373-398.
38. Hubbard S.R., Wei L., Ellis L., Hendrickson W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature. 372:1994;746-754.
39. Humphrey P.A., Wong A.J., Vogelstein B., Zalutsky M.R., Fuller G.N., Archer G.E., Friedman H.S., Kwatra M.M., Bigner S.H., Bigner D.D. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc. Natl. Acad. Sci. USA. 87:1990;4207-4211.
40. Huse M., Kuriyan J. The conformational plasticity of protein kinases. Cell. 109:2002;275-282.
41. Jorissen R.N., Walker F.W., Pouliot N., Garrett T.P.J., Ward C.W., Burgess A.W. Epidermal growth factor receptor. mechanisms of activation and signalling Exp. Cell Res. 284:2003;31-53.
42. Jungbluth A.A., Stockert E., Huang H.J., Collins V.P., Coplan K., Iversen K., Kolb D., Johns T.J., Scott A.M., Gullick W.J.et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc. Natl. Acad. Sci. USA. 100:2003;639-644.
43. Karunagaran D., Tzahar E., Beerli R.R., Chen X., Graus-Porta D., Ratzkin B.J., Seger R., Hynes N.E., Yarden Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors. implications for breast cancer EMBO J. 15:1996;254-264.
44. Koeppen H.K.W., Wright B.D., Burt A.D., Quirke P., McNicol A.M., Dybdal N.O., Sliwkowski M.X., Hillan K.J. Overexpression of HER2/neu in solid tumors. An immunohistochemical survey Histopathology. 38:2001;96-104.
45. Kohda D., Odaka M., Lax I., Kawasaki H., Suzuki K., Ullrich A., Schlessinger J., Inagaki F. A 40-kDa epidermal growth factor/transforming growth factor α-binding domain produced by limited proteolysis of the extracellular domain of the epidermal growth factor receptor. J. Biol. Chem. 268:1993;1976-1981.
46. Landgraf R., Eisenberg D. Heregulin reverses the oligomerization of HER3. Biochemistry. 39:2000;8503-8511.
47. Lax I., Burgess W.H., Bellot F., Ullrich A., Schlessinger J., Givol D. Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol. Cell. Biol. 8:1988;1831-1834. a.
48. Lax I., Johnson A., Howk R., Sap J., Bellot F., Winkler M., Ullrich A., Vennstrom B., Schlessinger J., Givol D. Chicken epidermal growth factor (EGF) receptor. cDNA cloning, expression in mouse cells, and differential binding of EGF and transforming growth factor alpha Mol. Cell. Biol. 8:1988;1970-1978. b.
49. Lax I., Bellot F., Howk R., Ullrich A., Givol D., Schlessinger J. Functional analysis of the ligand binding site of EGF-receptor utilizing chicken/human receptor molecules. EMBO J. 8:1989;421-427.
50. Lax I., Bellot F., Honegger A.M., Schmidt A., Ullrich A., Givol D., Schlessinger J. Domain deletion in the extracellular portion of the EGF-receptor reduces ligand binding and impairs cell surface expression. Cell Regul. 1:1990;173-188.
51. Lemmon M.A., Bu Z., Ladbury J.E., Zhou M., Pinchasi D., Lax I., Engelman D.M., Schlessinger J. Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J. 16:1997;281-294.
52. Mendrola J.M., Berger M.B., King M.C., Lemmon M.A. The single transmembrane domains of erbB receptors self-associate in cell membranes. J. Biol. Chem. 277:2002;4704-4712.
53. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61:2001;4744-4749.
54. Odaka M., Kohda D., Lax I., Schlessinger J., Inagaki F. Ligand-binding enhances the affinity of dimerization of the extracellular domain of the epidermal growth factor receptor. J. Biochem. (Tokyo). 122:1997;116-121.
55. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., Saito K., Sakamoto A., Inoue M., Shirouzu M., Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell. 110:2002;775-787.
56. Padhy L.C., Shih C., Cowing D., Finkelstein R., Weinberg R.A. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell. 28:1982;865-871.
57. Paik S., Liu E.T. HER2 as a predictor of therapeutic response in breast cancer. Breast Disease. 11:2000;91-102.
58. Penuel E., Akita R.W., Sliwkowski M.X. Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association. J. Biol. Chem. 277:2002;28468-28473.
59. Press M.F., Pike M.C., Hung G., Zhou J.Y., Ma Y., George J., Dietz-Band J., James W., Slamon D.J., Batsakis J.G.et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland. correlation with poor prognosis Cancer Res. 54:1994;5675-5682.
60. Ranson M., Sliwkowski M.X. Perspectives on anti-HER monoclonal antibodies. Oncology. 63(Suppl 1):2002;17-24.
61. Ross J.S., Fletcher J.A. The HER-2/neu oncogene in breast cancer. prognostic factor, predictive factor, and target for therapy Stem Cells. 16:1998;413-428.
62. Saxon M.L., Lee D.C. Mutagenesis reveals a role for epidermal growth factor receptor extracellular subdomain IV in ligand binding. J. Biol. Chem. 274:1999;28356-28362.
63. Schaefer G., Akita R.W., Sliwkowski M.X. A discrete three-amino acid segment (LVI) at the C-terminal end of kinase-impaired ErbB3 is required for transactivation of ErbB2. J. Biol. Chem. 274:1999;859-866.
64. Schechter A.L., Stern D.F., Vaidyanathan L., Decker S.J., Drebin J.A., Greene M.I., Weinberg R.A. The neu oncogene. an erb-B-related gene encoding a 185,000-Mr tumour antigen Nature. 312:1984;513-516.
65. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 103:2000;211-225.
66. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 110:2002;669-672.
67. Schlessinger J. Signal transduction. Autoinhibition control. Science. 300:2003;750-752.
68. Sizeland A.M., Burgess A.W. Anti-sense transforming growth factor alpha oligonucleotides inhibit autocrine stimulated proliferation of a colon carcinoma cell line. Mol. Biol. Cell. 3:1992;1235-1243.
69. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer. correlation of relapse and survival with amplification of the HER-2/neu oncogene Science. 235:1987;177-182.
70. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., Press M.F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
71. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M.et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:2001;783-792.
72. Sliwkowski M.X., Lofgren J.A., Lewis G.D., Hotaling T.E., Fendly B.M., Fox J.A. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26(Suppl. 12):1999;60-70.
73. Stamos J., Sliwkowski M.X., Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277:2002;46265-46272.
74. Summerfield A.E., Hudnall A.K., Lukas T.J., Guyer C.A., Staros J.V. Identification of residues of the epidermal growth factor receptor proximal to residue 45 of bound epidermal growth factor. J. Biol. Chem. 271:1996; 19656-19659.
75. Tzahar E., Pinkas-Kramarski R., Moyer J.D., Klapper L.N., Alroy I., Levkowitz G., Shelly M., Henis S., Eisenstein M., Ratzkin B.J.et al. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J. 16:1997;4938-4950.
76. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 61:1990;203-212.
77. Ushiro H., Cohen S. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J. Biol. Chem. 255:1980;8363-8365.
78. Walker F., Hibbs M.L., Zhang H.H., Gonez L.J., Burgess A.W. Biochemical characterization of mutant EGF receptors expressed in the hemopoietic cell line BaF/3. Growth Factors. 16:1998;53-67.
79. Ward C.W., Garrett T.P.J. The relationship between the L1 and L2 domains of the insulin and epidermal growth factor receptors and leucine-rich repeat modules. BMC Bioinformatics. 2:2001;4.
80. Ward C.W., Hoyne P.A., Flegg R.H. Insulin and epidermal growth factor receptors contain the cysteine repeat motif found in the tumor necrosis factor receptor. Proteins: Struct. Funct. Genet. 22:1995;141-153.
81. Ward C.W., Garrett T.P.J., McKern N.M., Lou M., Cosgrove L.J., Sparrow L.G., Frenkel M.J., Hoyne P.A., Elleman T.C., Adams T.E.et al. The three dimensional structure of the type I insulin-like growth factor receptor. Mol. Pathol. 54:2001;125-132.
82. Wiesmann C., Fuh G., Christinger H.W., Eigenbrot C., Wells J.A., de Vos A.M. Crystal structure at 1.7Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell. 91:1997;695-704.
83. Wiesmann C., Ultsch M.H., Bass S.H., de Vos A.M. Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor. Nature. 401:1999;184-188.
84. Woltjer R.L., Lukas T.L., Staros J.V. Direct identification of residues of the epidermal growth factor receptor in close proximity to the amino terminus of bound epidermal growth factor. Proc. Natl. Acad. Sci. USA. 89:1992;7801-7805.
85. Wu D.G., Wang L.H., Chi Y., Sato G.H., Sato J.D. Human epidermal growth factor receptor residue covalently cross-linked to epidermal growth factor. Proc. Natl. Acad. Sci. USA. 87:1990;3151-3155.
86. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology. 61(Suppl 2):2001;1-13.
87. Yarden Y., Sliwkowski M.X. Untangling the erbB signalling network. Nature Reviews (Mol. Cell. Biol.). 2:2001;127-137.
88. Zhen Y., Caprioli R.M., Staros J.V. Characterization of glycosylation sites of the epidermal growth factor receptor. Biochemistry. 42:2003;5478-5492.